Pfizer
Thermo Fisher Scientific, Pfizer Canada Grant C$300K to Study NGS in Colorectal Cancer Care
The recipients of both grants will study the effects of bringing next-generation sequencing-based testing into a community cancer center.
FDA Approves Foundation Medicine CDx Tests for Pfizer's Braftovi-Mektovi Combo in Lung Cancer
The FoundationOne CDx and FoundationOne Liquid CDx tests were approved to determine whether patients with metastatic non-small cell lung cancer may be eligible for treatment.
Ginkgo Bioworks, Pfizer Ink RNA Drug Discovery Deal Worth up to $331M
The deal is the latest multimillion-dollar collaboration to come out of Ginkgo Bioworks' concerted effort to court the pharmaceutical industry in 2023.
Duke Researchers Use Veracyte Data to ID Prostate Cancer Subgroups for Added Post-Surgery Treatment
Premium
The recent JCO Precision Oncology study could bolster the research use case for Veracyte's Decipher GRID database in better defining prostate cancer subgroups.
Foundation Medicine Blood Test Gets FDA Approval as CDx for Pfizer's Braftovi in Colorectal Cancer
The FDA has approved the FoundationOne Liquid CDx assay to identify patients with BRAF V600E alterations eligible for treatment with Braftovi.